ShareSpot

  • Bictegravir Approved for Initial ART, in Combination with TAF/FTC

    Susa Coffey's picture

    Bictegravir (BIC), a new integrase inhibitor, was recently approved by the FDA for use in a single-pill coformulation with TAF/FTC (brand name: Biktarvy) as initial therapy and as a switch regimen for patients who are already on a suppressive ART regimen and who have no history of...

  • Bictegravir/TAF/FTC in Women

    Susa Coffey's picture

    The single-pill combination of bictegravir (BIC) with tenofovir alafenamide (TAF) and emtricitabine (FTC), recently approved by the FDA, has been shown in four Phase III trials to be effective as initial therapy and as a switch regimen in patients with stably suppressed HIV RNA...

  • Immediate ART Initiation Improves Time to Viral Suppression

    Susa Coffey's picture

    The availability of ART immediately after the diagnosis of HIV offers many possible benefits, including earlier engagement in care and earlier HIV suppression, which may result in personal and public health benefits. Based on randomized clinical trials done in developing-world settings, the...

  • Short Bites: Human Papillomavirus (HPV) Update

    HPV oral and oropharyngeal cancers are more difficult to detect than tobacco-related cancers because the symptoms are not always obvious to an individual, and health professionals may lack the education and background to diagnose HPV-related lesions. Although there are many adjunctive oral...

  • Transitioning Your HIV Practice to a New Doctor

    The AIDS epidemic raged around me like a wildfire in the late '80s and early '90s while I trained in medicine in San Francisco. During that storm, I began working with people living with HIV. In 1995, ready to start a primary medical practice, I landed at a community clinic in Berkeley, California...
  • Forever Grateful: My Experience as a Rutgers HIV Care Specialization Student

    Samantha N. Anderson's picture

    While enrolled in graduate school at the Rutgers University School of Nursing, I continued to work as registered nurse on a labor and delivery unit at an increasingly busy community hospital in central New Jersey. Though my unit boasts delivery rates exceeding 2,000 births per year, most of our...

  • Non-Occupational Post-Exposure Prophylaxis (nPEP) in Rural Areas – Does It Exist?

    Nurses are on the front-lines of increasing access to health care and, as a nurse, my first priority is always the patient. A recent case demonstrates the importance of the role of nursing in providing needed services for patients. In this case, a young person was a victim of sexual assault...

  • Short Bites: What Is a Dental Emergency?

    What is a dental emergency? 

    I often get this question from non-dental personnel including case managers, physician assistants, nurses, and nurse practitioners. The following is a short list of questions you can ask patients to guide dental referrals for emergency...

  • Undetectable = Untransmittable: Effective HIV Treatment Prevents HIV Transmission

    Susa Coffey's picture

    In September 2017, the U.S. Centers for Disease Control and Prevention (CDC) officially recognized that suppressing HIV through antiretroviral therapy (ART) prevents sexual transmission of HIV. In a "Dear Colleague" letter, CDC officials said, "people who take ART daily as prescribed and...

  • Short Bites: Effects of Antiretroviral Therapy (ART) on Oral Lesions

    A recent study that was conducted among 1200 HIV patient of whom 600 each belonged to with ART and without ART and the occurrence of oral candidiasis and oral hairy leukoplakia. This study shows that oral candidiasis and leukoplakia was less among patients on ART as well as a decrease in the...

  • Short Bites: Do I Pre-medicate Patients Based on a High Viral Load and Low CD4 Count?

    The question I most commonly get asked by oral health providers is...

    Do I pre-medicate patients based on a high viral load and low CD4 count?

    There is no supporting data to support the need for routine antibiotic coverage pre or post dental treatment based on the...

  • Short Bites: Xerostomia in Patients Living with HIV

    It is estimated that 1.1 million people in the United States are living with HIV. Of those, 1 in 7 do not know they are infected.[1] The number of new HIV diagnoses fell 19% from 2005 to 2014.[1] Because HIV testing rates have remained stable or increased in recent years, this decrease in...

  • Short Bites: Periodontal Health in the Era of Antiretroviral Therapy

    The U.S. Department of Health and Human Services currently recommends that every person living with HIV begin antiretroviral therapy (ART) as soon as possible after diagnosis. Increased availability of testing and treatment along with the above guidelines have reduced the number of new HIV...

  • Short Bites: One in Nine American Men are Infected with Oral HPV

    According to a new study published in the Journal Annals of Internal Medicine, one in nine American men is infected with the oral form of the human papillomavirus (HPV). Nationwide, rates of oral HPV infection are 11.5% of men vs. 3.2% women. HPV 16, the most common type of high-risk HPV and...

  • Giving New Life to New Jersey Syringe Access Programs

    I had the honor to help develop the first legal syringe access program (SAP) in Atlantic City, NJ, almost 10 years ago. In 2006, the New Jersey legislature passed the Blood-Borne Disease Harm Reduction Act, which allowed for the establishment of up to six pilot SAPs in NJ; however, approval from...

  • Doravirine in Initial Therapy: DRIVE-AHEAD Study

    Susa Coffey's picture

    Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the...

  • On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen

    Jennifer Cocohoba's picture

    The EMERALD Study is a Phase 3 randomized (2:1), open-label, noninferiority study examining the strategy of switching patients with suppressed HIV RNA on a regimen consisting of a boosted protease inhibitor plus tenofovir disoproxil fumarate (TDF)/emtricitabine to an investigational single-...

  • Bictegravir in Initial Therapy

    Susa Coffey's picture

    Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG)...

  • Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference

    Laura Cheever's picture

    Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair

    The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...

  • Evolving: A Journey in Practice Transformation

    Kirsten R Corrigan's picture

    I remember driving to Chicago on my first day as a Midwest AETC Practice Transformation (PT) Coach filled with both excitement and apprehension to participate in a 3-day intensive training titled Building Blocks of High Performing Primary Care. While the concepts of PT were familiar to me after...